Analyst Sean Laaman from Axsome Therapeutics has issued a price target of $190.00 for the company’s stock, $AXSM, with 3 analysts reporting a median target of $162.00 over the past six months.
Insider trading activity for $AXSM has shown that there have been 13 trades in the past six months, all of which were sales with no purchases. Notably, COO Mark L. Jacobson sold 65,673 shares for approximately $6,993,636.
In the latest quarter, 182 institutional investors increased their holdings in $AXSM, while 139 decreased their positions. Significant movements include RTW Investments removing 1,128,636 shares (-27.9%) and Assenagon Asset Management adding 623,717 shares (+16852.7%).
